Orthocell (ASX: OCC)

Initiation of Coverage – Tuesday 20 March 2018

Growing with CelGro®

Orthocell is an emerging player in the multi-billion-dollar field of regenerative medicine. Its unique foundation products (Ortho-ATI™ for tendon repair and Ortho-ACI™ for cartilage repair) provide early commercial opportunities with large addressable markets. But, the big payday may occur this financial year with European approval (CE Mark) achieved for CelGro® and US approval to follow. CelGro® is the company’s collagen scaffold that facilitates rapid tissue regrowth across a range of indications. We regard CelGro® as a potential breakthrough product due to its mechanical strength, natural collagen structure and versatility. CelGro® could also enjoy rapid initial revenue in dental and orthopaedic markets - potentially accelerated by commercial partnerships with large healthcare companies. CelGro®’s potential market is well in excess of US$2bn. Orthocell has further related and ground-breaking opportunities including its ‘Cell Factory’ project to harness stem cell growth factors. Our target price for the company is A$1.75 per share (midpoint of base case: A$0.89 and optimistic case: A$2.63).

Rating
Buy

Risk
Speculative

Current price
$0.29

Target price
$1.75

Stock details
Daily Turnover: ~A$36,000
Market Cap: A$32.4m
Shares Issued: 110.0m
52-Week High: $0.26
52-Week Low: $0.49

Analyst: Stuart Roberts
stuart@ndfresearch.com
+61 447 247 909

Please note: This report has been commissioned by Orthocell and NDF Research has received payment for its preparation. Please refer below for risks related to Orthocell as well our General Advice Warning, disclaimer and full disclosures. Also, please be aware that the investment opinion in this report is current as at the date of publication but that the circumstances of the company may change over time, which may in turn affect our investment opinion.
About NDF Research

NDF is an independent equity research firm based in Sydney, Australia. It focuses on Life Science companies that are publicly traded on the Australian Securities Exchange (ASX), most of which are headquartered in Australia and New Zealand. ASX hosts one of the world’s premier equity markets for biotech and medical device companies, and is home to world-beating companies such as CSL and ResMed and emerging pioneers such as Mesoblast and Impedimed.

NDF’s Founder and Senior Analyst, Stuart Roberts, has been involved in Life Sciences since 2002 as a sell-side analyst as well as an executive of two ASX-listed immuno-oncology drug developers.

NDF believes that ASX-listed companies have been largely overlooked in the global Life Sciences boom that began in late 2008, partly because of insufficient quality research. NDF’s goal is to provide such research, and introduce investors around the world to potential future billion-dollar companies from ‘Down Under’.

To learn more about the Life Sciences sector on the ASX and our firm, please visit ndfresearch.com.
## In this report

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introducing Orthocell, ASX: OCC</td>
<td>4</td>
</tr>
<tr>
<td>Ten reasons to look at Orthocell</td>
<td>6</td>
</tr>
<tr>
<td>Ortho-ATI® – A world-first tendon repair product</td>
<td>7</td>
</tr>
<tr>
<td>Ortho-ACI® – The most advanced Autologous Cartilage Implantation product available</td>
<td>12</td>
</tr>
<tr>
<td>CelGro® – Possibly the best tissue engineering scaffold invented</td>
<td>13</td>
</tr>
<tr>
<td>Orthocell is growing its pipeline of regenerative medicine opportunities</td>
<td>18</td>
</tr>
<tr>
<td>Valuing Orthocell</td>
<td>19</td>
</tr>
<tr>
<td>Re-rating Orthocell</td>
<td>23</td>
</tr>
<tr>
<td>Orthocell’s leadership</td>
<td>23</td>
</tr>
<tr>
<td>Appendix I – An Orthocell glossary</td>
<td>24</td>
</tr>
<tr>
<td>Appendix II – Orthocell’s intellectual property</td>
<td>27</td>
</tr>
<tr>
<td>Appendix III – Capital structure summary</td>
<td>28</td>
</tr>
<tr>
<td>Appendix IV – Orthocell’s major shareholders</td>
<td>28</td>
</tr>
<tr>
<td>Appendix V – Papers relevant to Orthocell</td>
<td>29</td>
</tr>
<tr>
<td>Appendix VI – Companies to watch</td>
<td>30</td>
</tr>
<tr>
<td>Risks related to Orthocell</td>
<td>32</td>
</tr>
<tr>
<td>General Advice Warning, Disclaimers &amp; Disclosures</td>
<td>33</td>
</tr>
</tbody>
</table>
Introducing Orthocell, ASX: OCC

Orthocell is a commercial-stage regenerative medicine company with a focus on cellular therapies and collagen medical devices for the repair of soft tissue injuries and musculoskeletal disorders.

Orthocell’s portfolio of products include the TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. Orthocell’s market leading tendon regeneration product is attracting interest from global health care companies. For example, Orthocell is recruiting patients for a clinical trial of Ortho-ATI®. The objective of this study is to assess the safety and effectiveness of Ortho-ATI® compared to corticosteroid injection in the treatment of rotator cuff tendinopathy and tear. The trial is being undertaken in collaboration with DePuy Synthes Products, Inc., part of the Johnson & Johnson Medical Device Companies.

The company’s other major product is CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. Orthocell recently received European regulatory approval (CE Mark) for CelGro®. The collagen medical device can now be marketed and sold within the European Union for a range of dental bone and soft tissue regeneration procedures and is being readied for first approval in the US.

At the early research stage are the ‘Lab-Grown Tendon’ project, where human tendons grown in a bioreactor may be used in tendon repair; and the ‘Cell Factories’ project in which growth factors from stem cells are used for allogeneic therapies.

What is regenerative medicine and why is it significant in today’s healthcare setting? Regenerative medicine is the use of drugs and medical devices to harness the power of stem cells and related growth factors for repairing damaged tissues and organs. This is regarded as significant because up until recently there was no way for physicians to easily repair damaged soft tissue and bone, such as hearts, joints and spinal cords. Regenerative medicine promises to be the tool to make this possible. For musculoskeletal conditions in particular, the potential is for the first ever disease-modifying therapies. Where, for example, hyaluronic acid and steroids simply provide some pain relief, tissue repair using scaffolds and/or stem cells can repair the damaged tissue responsible for that pain. By being minimally invasive, and focused on the pathology not just the symptoms, such therapies can be highly cost-effective. For example, 12% of all osteoarthritis is due to traumatic joint injury. Proper joint repair will significantly lower the incidence of osteoarthritis in these patients.

How is Orthocell a serious regenerative medicine player? One of Orthocell’s most notable achievements in the regenerative medicine field to date is the development of Ortho-ATI®, the first autologous therapy in the world for the treatment of tendon damage. Orthocell have demonstrated that Ortho-ATI® has significant clinical and commercial potential. On 9 November 2017 the company announced regulatory approval (CE Mark) for the marketing and distribution of CelGro® in various dental bone and soft tissue regeneration procedures in the EU.

---

This is the first product of a diverse suite of collagen medical devices to be commercialised from Orthocell’s CelGro® platform. CelGro® is arguably one of the best tissue repair scaffolds yet invented. Further down the track, Orthocell could potentially be the first company to develop ‘cell factories’ for allogeneic tissue repair.

**Why is CelGro® a potential ‘breakthrough’ product for Orthocell?**

Often in tissue repair, biocompatible scaffolds are used in order to allow new tissue to grow into place. CelGro®, which consists of high-purity natural collagen, is unique in that it is completely acellular, has ideal mechanical properties and the right ‘integration profile’ to hasten in-growth of tissue at the site of the scaffold. It also has a tunable ‘degradation profile’ once the new tissue is in place. Orthocell argues that the result is high-quality tissue repair in a range of applications, with numerous clinical studies currently ongoing expected to verify this.

**Why is the CE Mark so important?**

The CE Mark allows CelGro® to be sold within EU countries and provides a strong foundation for additional dental bone and soft tissue regeneration regulatory applications in other key markets such as the US. Orthocell has a clear commercialisation strategy in place to drive initial sales of CelGro® and the company is in discussion with strategic commercial partners for product distribution in Europe and other key regions. Orthocell is also currently in discussions with selected Key Opinion Leaders in the dental and bone regeneration fields, who play an important role in driving broader market adoption. The CE Mark also validates the potential of the entire technology platform by endorsing CelGro®’s clinical performance and quality manufacturing, and by enabling other potential future indications, including peripheral nerve repair and hernia repair.

**What are autologous and allogeneic therapies, and which is more important in the regenerative medicine field?** In autologous therapy, a patient’s own tissue is engineered and given back to them. Autologous therapies tend to be expensive because of the need to individually manufacture each dose. By contrast allogeneic therapies, where recipients receive tissue or stem cells from unrelated donors, will be lower-cost because they can be marketed ‘off-the-shelf’. However allogeneic therapies are, at this stage, not suitable for every indication in regenerative medicine. In tendon repair, for example, allogeneic cell sources are very difficult to achieve where typically Mesenchymal Stem Cells will not engraft into the tendon and will only act as a stimulus.

Orthocell’s autologous therapies are cost-effective because they are ‘fit for purpose’ and work better than current commercially-available alternatives.

**If Orthocell is so good, why is it currently capitalised at only US$24.9m (A$31.9m)?** We believe that most publicly traded biotech and medical device companies in the regenerative medicine field are undervalued because of historical debates over the ethical use of stem cells in medicine and because of the fact that most stem cell therapies are still in clinical development. We believe the recent encouraging article in the *New England Journal of Medicine* from FDA commissioner Scott Gottlieb and his colleague Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, on stem cell regulation will help change public perceptions on the sector.

Meantime, for Orthocell, its second breakthrough product has achieved regulatory approval in Europe and its tissue-engineering processes are non-controversial. The recent achievement of the CE Mark approval has derisked CelGro®. We expect further regulatory approvals of CelGro® in other jurisdictions (such as the US) and across

---

2 See, for example, J Shoulder Elbow Surg. 2012 Feb;21(2):278-94.
other indications (such as nerve, tendon and ligament) to provide key catalysts for the stock, by validating the Orthocell platform and providing more understanding of its many big-market applications.

Ten reasons to look at Orthocell

1) **Regenerative medicine is becoming big business.** With International health authorities focusing on accelerating the introduction of regenerative medicine through accommodating policies; with sophisticated stem cell products performing well in late stage clinical trials; and with products like CelGro® gaining their first regulatory approval, we believe we are in the early stages of a boom in regenerative medicine.

2) **The market for repairing damaged tissue is significant.** Injuries such as tennis elbow and ACL rupture are commonplace not just in sport but in life and work. Musculoskeletal conditions accounted for approximately 8% of the global disease burden in 2010 so there are multi-billion-dollar opportunities for the best, most cost-effective therapies. The acquisition of LifeCell by Allergan in February 2017 for US$2.9bn, and Rotation Medical by Smith & Nephew for US$125m upfront in October 2017, illustrates the upside for companies that are successful in this field.

3) **Orthocell’s Ortho-ATI® is a market-leading product,** as the only regenerative-medicine-based product currently available for the repair of damaged tendons.

4) **Orthocell has received its first regulatory approval for CelGro®, with other major markets to follow.** CelGro® is a platform technology with multiple applications including bone, tendon, nerve and cartilage repair. The product has performed well in numerous clinical studies since 2015.

5) **The upside for CelGro® in the dental field is particularly significant,** with advances in dental implant technology driving the need for membranes that can work with bone graft substitutes.

6) **Orthocell’s portfolio of regenerative medicine technologies are attracting interest from global health care companies.** For example, Orthocell is recruiting patients for a clinical trial of Ortho-ATI®. The objective of this study is to assess the safety and effectiveness of Autologous Tenocyte Injection (Ortho-ATI®) compared to corticosteroid injection in the treatment of rotator cuff tendinopathy and tear. The trial is being undertaken in collaboration with DePuy Synthes Products, Inc., part of the Johnson & Johnson Medical Device Companies.

7) **Ortho-ACI® has been a dependable foundation product,** with considerable advantages over earlier chondrocyte injection therapies. Ortho-ACI® has been marketed by Orthocell since 2010, with over 480 patients treated to date.

8) **Orthocell is working on allogeneic products.** The company’s ‘Lab-Grown Tendon’ and ‘Cell Factories’ projects have the potential to become the Next Big Things in tissue engineering.

---

4 Around 5% of the US population is physically active every day of the week – source: Sports and Fitness Industry Association, 2013 Sports, Fitness and Leisure Activities Topline Participation Report.

9) **Orthocell has a solid management team.** Founder and CEO Paul Anderson has built the company over ten years into a regenerative medicine contender with autologous products on the market and allogeneic projects in the pipeline. We are backing Anderson and the executive team as they have skills and previous success in building revenue-stage Life Sciences companies.

10) **Orthocell is undervalued, on our numbers.** We value Orthocell at A$0.89 per share (base case) and A$2.63 (optimistic case) using a probability-weighted DCF-based valuation of the lead products. Our A$1.75 per share price target sits at about the midpoint of our valuation range.

---

### Ortho-ATI® – A world-first tendon repair product

**Tendon repair is an area of unmet medical need.** Tendons are the fibrous connective tissues in the body, mostly made from collagen, which attach muscles to bone and help those bones to move. Tendons are easily injured because they bear much of the stress when the muscle contracts, and they are less vascularised than muscle, making them slower to heal when damaged. Consequently, tendon injury, called tendinopathy, is commonplace in advanced industrial countries. And yet, in spite of this, ‘the ideal treatment for tendinopathy’, as one reviewer recently put it, ‘is still nebulous’.

- **Tendinopathy is a large market opportunity.** There are no exact figures on the prevalence of all tendinopathies however it could be >6% of the adult population.
- **Standard of care for tendinopathy is still being worked out.** Traditionally tendinopathy has been treated in the first instance with anti-inflammatories such as corticosteroids, with only short-term benefit, and if the injury is slow to heal, with surgery. Two more recent trends have been ‘needling’ and ‘platelet-rich plasma’ (PRP), where a common aim in each case is to harness growth factors that will prompt tissue regeneration. In needling, a special needle is thrust into the tendon to make it bleed and bring about the influx of growth factors. PRP takes advantage of the fact that the platelet-derived growth factors in such a blood product can do likewise, although there is a paucity of controlled, randomised studies on duration of effect.

**Orthocell clinical data suggests its Ortho-ATI® is a superior tendon repair product.** Ortho-ATI®, initially developed in 2006, is Orthocell’s Autologous Tenocyte Implantation treatment for tendinopathy. In an Ortho-ATI® procedure, a sample of healthy tendon tissue is biopsied from the patient (usually from the patellar tendon near the knee), with the tenocytes from those cells expanded in Orthocell’s laboratory in the Australian city of Perth over a 4-to-6 week period, after which they are returned to the patient. The product grew out of an insight

---

6. Tendons also connect muscles to other structures such as the eyeballs.
8. See, for example, J Rheumatol. 2007 May;34(5):1076-82. Epub 2007 Mar 1.
from Orthocell founder Professor Ming-Hao Zheng that tenocytes, the characteristic cells in tendons, were slow growing but that phenotypically stable tenocytes could nonetheless be cultured in therapeutically relevant numbers and in a reasonable time-frame in a culture medium. Once these new tenocytes were in place they could pump out the right kind of collagen and other non-collagenous matrix proteins that would restore a cohesive tendon with normal structure and function. Orthocell’s clinical data suggests Ortho-ATI® is a superior tendon repair approach to needling, PRP and other therapies because no other approach can put these important building blocks of tendons in place. This insight led to a global regenerative medicine breakthrough – in 2010 Ortho-ATI® became the first approved cell therapy for tendon repair in the world, and the clinical evidence behind Ortho-ATI® has grown considerably since then.

The data on Ortho-ATI® has been very good so far. Five main human studies have borne out the clinical effectiveness of Ortho-ATI® in tendinopathy to date. An original clinical study in 2008 in tennis elbow established the product’s early clinical effectiveness and durability, while an as-yet-unpublished study from 2015 in severely-affected tennis elbow patients showed that Orthocell’s product could work after everything else had failed.

- **A Phase 1 study in Lateral Epicondylitis, 2008-2015.** This study, which commenced in 2008, tracked 17 patients in Perth with Lateral Epicondylitis after they received Ortho-ATI®. Lateral Epicondylitis is commonly called ‘tennis elbow’. Orthocell’s tennis elbow patients, whose condition was over six months old at the time of treatment, registered a statistically significant (p < 0.001) reduction in pain scores (86% mean reduction over 12 months), an improvement in grip strength (85% mean increase over 12 months), an improvement in overall elbow function (94% mean increase over 12 months), and an improvement in the grade of tendinopathy, as measured by MRI. This data was published in the *American Journal of Sports Medicine* in September 2013. The *American Journal of Sports Medicine* also published, in April 2015, long-term follow up data with average duration of 4.5 years showing that Ortho-ATI® was genuinely disease-modifying. This data, which first became available in August 2014, showed that, over time, the patients’ grip strength continued to improve (from 85% over baseline at 12 months to 207% over baseline at 4.5 years) while the initial reduction in pain scores and improvement in elbow function were maintained (83% versus 86% and 87% versus 94% respectively). The data set for this study was one of the longest assembled for a cellular therapy up to that time.

---

15. Even though most of the cells in tendons are fibroblasts, endothelial cells, synovial cells and chondrocytes.
17. One study which has yet to read out data is a double-blind, placebo controlled trial in Achilles tendinopathy which commenced in 2011 at Erasmus Medical Center in the Dutch city of Rotterdam (see NCT01341896 at www.clinicaltrials.gov). The study recruited 90 patients with Achilles tendon injuries who had failed a prescribed exercise regime. Half the patients received Ortho-ATI® and half received saline injections. The study had completed recruitment by December 2013. The primary endpoint of the trial was a reduction in the severity of Achilles tendinopathy, as measured by a questionnaire-based ratings scale called ‘VISA-A’. Data has been expected to read out in mid-2015 however we understand a suitable journal in which to publish is being sought.
18. The ANZCTR trial ID for this study is ACTRN12607000402448 – see www.anzctr.org.au.
20. Measured by how many kilograms worth of weight the patient can pick up.
21. quickDASH.
24. See the company’s market release dated 25 August 2014 and headlined ‘Clinical study shows long-term effectiveness of Orthocell’s Ortho-ATI® for treatment-resistant tennis elbow’ and the company’s 2 September 2014, Investor Presentation.
- **Phase 1 study in gluteal tendinopathy, 2010-2017.** This study, which commenced in 2010, evaluated 12 patients with serious gluteal tendinopathy where the average symptom duration had been 33 months and where patients had failed all previous therapies\(^25\). Damage to the gluteal tendons affects hip and thigh movement. Orthocell reported in 2014 that 8 of the 12 patients reported that they were ‘satisfied’ or ‘highly satisfied’ with the treatment after 12-months\(^26\). In November 2014, the company disclosed two-year data from the 12 patients showing statistically significant reductions in pain scores (VAS), an improvement in hip function (Oxford Hip Score) and an improvement in quality of life (SF36 PCS)\(^27\). In December 2016 Orthocell indicated that the average quality-of-life increase had been 148%\(^28\). The data was finally published in the *Orthopaedic Journal of Sports Medicine* in February 2017\(^29\). Gluteal tendinopathy may affect >23.5% of women and >8% of men over the age of 50\(^30\).

- **Case study in rotator cuff injury, 2011-2013.** In 2011 Ming-Hao Zheng and his colleagues administered Ortho-ATI® to a 20-year-old elite gymnast with a rotator cuff tendon injury. Damage to these tendons impacts the ability of a person to rotate their shoulder, something vitally important to gymnasts. At the 12-month timepoint after receiving Ortho-ATI®, Zheng’s gymnast was reporting substantial improvement of clinical symptoms and was back in competition. This favourable outcome was reported in the journal *BMJ Case Reports* in January 2013\(^31\).

- **Study in severely-affected Lateral Epicondylitis patients on Workers’ Compensation, 2015.** Orthocell reported in October 2015 that Ortho-ATI® had proved effective in the treatment of 25 people with work-related Lateral Epicondylitis where the injury had inhibited their ability to work, where those patients had failed other modes of therapy, and where the symptoms had persisted for an average of 22 months. Ortho-ATI® was able to return 88% of these patients to work, most within 1-3 months, with a return to pre-injury productivity by a little over five months\(^32\). Orthocell has indicated that it intends to publish this retrospective data in a suitable journal.

- **Case study in rotator cuff injury, 2017.** In this case study an elite swimmer returned pain-free to full training, and international-level competition only four months after treatment\(^33\). This favourable outcome was reported in the *Physical Therapy in Sport* journal in October 2017.

- **Study in Lateral Epicondylitis patients comparing Ortho-ATI® to conventional surgery – data to come.** Orthocell announced in July 2016 a study at The Avenue Hospital in Melbourne that will compare Ortho-ATI® with surgery in Lateral Epicondylitis, with 25 patients in each treatment arm\(^34\). Recruitment to this study is expected to be completed in mid-2018.

**Collaboration with DePuy Synthes Products, Inc., part of the Johnson & Johnson Medical Device Companies.** Orthocell is recruiting patients for a clinical trial of Ortho-ATI®. The objective of this study is to assess the safety

---

\(^{25}\) The ANZCTR trial ID for this study is ACTRN12612000383864 – see www.anzctr.org.au.

\(^{26}\) Source: Orthocell May 2014 prospectus, page 26.

\(^{27}\) See Orthocell’s 24 November 2014 Annual General Meeting presentation.

\(^{28}\) See Orthocell’s December 2016 corporate presentation slide 15.


\(^{32}\) See Orthocell’s 28 October 2015 market release headlined ‘Ortho-ATI® tendon treatment positive in Workers’ Compensation study’.


\(^{34}\) See Orthocell’s 12 July 2016 market release headlined ‘Orthocell receives ethics approval for pivotal Ortho-ATI® tendon study’. The ANZCTR trial ID for this study is ACTRN12616000458437 – see www.anzctr.org.au.
and effectiveness of Autologous Tenocyte Injection (Ortho-ATI®) compared to corticosteroid injection in the treatment of rotator cuff tendinopathy and tear. The trial is being undertaken in collaboration with DePuy Synthes Products, Inc., part of the Johnson & Johnson Medical Device Companies. The study recruited its first patient in September 2017. We expect, if the study is successful, this may roll over to become a pivotal study.

**The two big indications – tennis elbow and rotator cuff injury.** Possibly 2-3% of the adult population has rotator cuff tendinopathy and around 1-2% each have Lateral Epicondylitis as well as a related condition called Medial Epicondylitis (commonly called ‘golfer’s elbow’). We argue below that tennis elbow and rotator cuff alone can create sizeable commercial opportunities for Orthocell and whoever chooses to partner with the company to take Ortho-ATI® forward.

**Orthocell has optimised its manufacturing for Ortho-ATI® over the last seven years.** Orthocell brought Ortho-ATI® onto the Australian market in 2010 via the then-prevailing local regulations that licensed manufacturers of human tissue rather than approved individual human tissue products. In Orthocell’s case, the company set up an ISO-14644-1 compliant GMP manufacturing facility on the campus of Murdoch University in Perth’s southern suburbs for which a license was granted in January 2010. In 2011, the Therapeutic Goods Administration (Australia’s version of the FDA) changed the regulations so that individual biologicals had to be approved, but grandfathered products such as Ortho-ATI® so long as the manufacturers filed a design dossier, which Orthocell did in 2013. Orthocell is continuing with its application for the inclusion of Ortho-ATI® on the Australian Register of Therapeutic Goods (ARTG), the official list of the country’s approved medical products, as a ‘Class 3 biological’. We believe this transition has eased the path towards gaining FDA and CE Mark approvals for Ortho-ATI® given the heavy emphasis that drug and medical device regulators are now placing on GMP manufacturing as part of their overview of product safety in the regenerative medicine field.

**Ortho-ATI® is starting to go global.** Currently Ortho-ATI® is available only in Australia and New Zealand, and, since 2015, in Hong Kong, but Orthocell now has big plans for the product in multiple new markets.

- **Australia/New Zealand, with the help of a contract sales force:** Locally, the patient numbers to date have been relatively small – around 450 over the last seven years. That said, the Australian business has proved a valuable testbed. Orthocell charges A$3,200 per injection for Ortho-ATI®, which it argues makes the product highly cost effective. Up until recently Orthocell itself handled marketing of Ortho-ATI® to radiologists, sports medicine specialists and physiotherapists in conjunction with select distributors. In October 2017 the company announced that a local medical device distributor called Surgical Specialties would handle distribution of Ortho-ATI® in the markets in which it is currently available, as well as the foundation Ortho-ACI® product we discuss below. We think this move is a good

---

37 The product gained an early use among various Australian athletes including AFL players – see Tendon relief hope in store by Daniel Hoy, Herald Sun, 22 August 2011.
38 Source: TGA, Australian Regulatory Guidelines for Biologicals, June 2011.
39 Class 2 biologicals as per the TGA’s classification criteria are minimally manipulated products while Class 3 and 4 are higher-risk, higher manipulation products – see Pathology. 2011 Oct;5(6):627-34.
41 See Orthocell’s 9 February 2015 market release dated 9 February 2015 and headlined ‘First patients in Hong Kong treated with Ortho-ATI® therapy’.
42 See Orthocell’s October 2017 corporate presentation, slide 17. At the time of Orthocell’s 2014 IPO the number of Ortho-ATI® implants was closer to 200 – see Orthocell’s May 2014 prospectus, page 22. Orthocell announced in November 2017 that the 1,000th patient for Ortho-ATI® and Ortho-ACI® had been treated.
one since it allows better training of surgeons and treating physicians, and allows Orthocell to learn about distribution ahead of the global roll-out of CelGro®.

- **The US:** Orthocell flagged in December 2016\(^43\) that it is preparing for a pre-IND meeting with the FDA ahead of a planned Phase 2 study in Lateral Epicondylitis. Orthocell now expects this meeting to take place in the second quarter of 2018 and the study to initiate shortly thereafter.

- **Japan:** Orthocell will likely seek to leverage the abridged approval process that currently applies in Japan for new regenerative medicines\(^44\).

**Rotator cuff is a US$6.5bn market opportunity for Ortho-ATI\(^\text{®}\.** Assume

- 1.5% of the population will suffer a rotator cuff injury in any one year\(^45\);
- 35% of these patients are symptomatic and will therefore seek treatment options\(^46\);
- 15% of the symptomatic patients will undergo arthroscopic rotator cuff surgery\(^47\) and the other 85% ‘conservative treatment’, such as steroids, hyaluronic acid injections\(^48\) and physical therapy;
- For the surgery patients, 33% of the procedures will not work\(^49\);
- For the non-surgical patients, 25% will not have satisfactory outcomes\(^50\).

Assume further that the surgery and non-surgery treatment failures then became candidates for Ortho-ATI\(^\text{®}.\) Across the billion people in the four major markets that Orthocell wishes to address\(^51\), this would represent 1.4 million patients. At US$4,500 per patient, a price that would likely be cost-effective given our estimate of US$15,000 for rotator cuff repair costs in the US\(^52\), Ortho-ATI\(^\text{®} is a US$6.5bn opportunity.

**Lateral Epicondylitis is a US$1.5bn market, at least.** Assume

- 0.3% of the population will suffer a from tennis elbow in any one year\(^53\);
- 10% of cases will prove refractory to conservative treatment and may transition to surgery\(^54\).

Assume further that patients that who would ordinarily be referred to surgery become candidates for Ortho-ATI\(^\text{®}. At US$4,500 per treatment, this would represent a US$1.5bn opportunity\(^55\). US$4,500 is cost effective here because around one in five patients with Lateral Epicondylitis still need care a year after first diagnosis\(^56\). Ortho-ATI\(^\text{®} has potential to markedly cut the cost of this care.

---

\(^43\) See the company’s December 2016 Corporate Update presentation, slide 17.
\(^44\) In November 2013 the Japanese Diet passed amendments to Japan’s Pharmaceutical Affairs Law defining new medical products which contain stem cells as ‘regenerative medicine products’. This will allow the Japanese Ministry of Health to give conditional approval to such products if their safety is confirmed after Phase 2.
\(^46\) J Orthop. 2013 Feb 26:10(1):8–12.  
\(^50\) US 327 million, EU 516 million, Japan 127 million, and Australia and New Zealand 28 million.  
\(^51\) Estimated from J Shoulder Elbow Surg. 2007 Mar-Apr;16(2):181-7, adjusted with BLS inflation data.  
\(^52\) Am J Sports Med. 2015 May;43(5):1266-71. Epub 2015 Feb 5. This contrasts with other estimates such as 1% to 3% of the adult population each year (Am J Sports Med. 2015 Sep; 43(9): 2133–2137) and reflects the fact that it is a population-based study rather than an estimate based on patient flow at a specialist clinic.  
\(^54\) That is, ~340,000 patients at US$4,500 each.  
Ortho-ACI® – The most advanced Autologous Cartilage Implantation product available

**Ortho-ACI® was Orthocell’s foundation product.** Ortho-ACI®, Orthocell’s cartilage repair product, was what enabled the company to be started in 2006. Autologous Chondrocyte Implantation, similar to Autologous Tenocyte Implantation, involves biopsying a sample of cartilage tissue from the patient, extracting and then expanding the chondrocytes from the cartilage, and returning them to the site of cartilage injury.

**Ortho-ACI® is a superior third-generation ACI product.** Orthocell did not invent Autologous Chondrocyte Implantation - it had been pioneered in the mid-1990’s by a group at the University of Göteborg in Sweden and then commercialised by a German company called Verigen. That company gained FDA approval for the product, which it called MACI and is now called Carticel, in 1997. The major US biotech company Genzyme acquired Verigen in 2005. Around that time Paul Anderson and Ming-Hao Zheng, who had brought Verigen’s product to Australia, set out to create a better ACI solution. What they ended up with, and were able to market from 2010 after the manufacturing facility was licensed, could best be described as ‘third generation’ ACI:

- The first generation ACI approach saw the chondrocytes kept in place at the site of the defect by way of a flap made out of periosteum, the outermost layer of bone. This was an effective therapy but had the problem of graft hypertrophy, where scar tissue formed around the edges of the periosteal flap.

- Second generation ACI solved the problem of keeping the chondrocytes in place through the use of bioengineered collagen or synthetic membranes as the placement agent. A recently approved second generation ACI, which is now marketed as MACI, was originally developed, as we noted above, by Verigen and Genzyme and is now a product of the US regenerative medicine company Vericel. MACI (Matrix-induced Autologous Chondrocyte Implantation), is cultured chondrocytes on a porcine collagen membrane for the treatment of full-thickness cartilage defects of the knee.

- Third generation ACIs such as Ortho-ACI® took the membrane idea a step further and used three-dimensionally constructed scaffolds that could grow cells faster and could be quickly fitted into place using fibrin glue. Ortho-ACI® uses a porcine-derived collagen scaffold. Typically for Ortho-ACI® the cell expansion process takes only 4-5 weeks versus closer to 8 weeks for first and second-generation approaches.

**Ortho-ACI® has a long history of clinical use now.** As with Ortho-ATI®, Ortho-ACI® was able to be used clinically in Australia without specific product approval through the tissue manufacturer regulations that existed prior to 2011. The product was included on the ARTG in May 2017. By then >380 patients had been treated. Orthocell reported retrospective data on 38 patients with articular cartilage defects in October 2015 showing 89% ‘good to

---

60 See Orthocell’s December 2016 corporate presentation, slide 19.
excellent’ outcomes on MRI assessment and 83% on arthroscopic assessment\(^6\). In Australia, Orthocell markets Ortho-ACI\(^®\) at A$6,500 per injection\(^6\). The company started offering Ortho-ACI\(^®\) in Singapore in November 2015.

**Ortho-ACI\(^®\) is a valuable product, but Orthocell now has bigger fish to fry.** In itself, Ortho-ACI\(^®\) is not as valuable as Ortho-ATI\(^®\) because there are competing ACI approaches for cartilage repair. That said, we expect there will be partnering opportunities for Ortho-ACI\(^®\) given the market need and the treatment outcomes that have been demonstrated to date. The real utility of Ortho-ACI\(^®\), however, is the collagen scaffold that was developed for it, which became Orthocell’s CelGro\(^®\) product.

**Ortho-ACI\(^®\) will compete is a >US$300m market globally.** Vericel estimates that the annual US incidence of full-thickness cartilage defects of the knee is 46,000 patients but that MACI’s market is only 14,000 patients once age (age 18-55 – the pivotal studies didn’t evaluate patients over 55\(^5\)), insurance status and level of physical activity is taken into account\(^6\). That said, at US$10,000 per procedure with Ortho-ACI\(^®\) there is probably a US$300m-350m opportunity across Orthocell’s target market.

**CelGro\(^®\) – Possibly the best tissue engineering scaffold invented**

**Tissue repair often just needs a decent scaffold, like Orthocell’s.** Scaffolds are a vital part of the stem cell and tissue engineering field today. As we’ve seen with Ortho-ACI\(^®\) above, generally if one wants to grow new tissue at the site of a wound or tissue defect, it’s not sufficient to lay down new cells at the site. These cells often need to be scaffolded with a device that can mimic the natural three-dimensional environment in which those cells would ordinarily grow, with the scaffold eventually being replaced by the extracellular matrix. The last fifteen years has seen a lot of development activity around new scaffolds. Orthocell argues that it has one of the best, with a collagen scaffold that can encourage natural tissue regeneration with or without the use of stem cell implants.

**CelGro\(^®\) has an ideal structure to promote rapid cell proliferation at the site of tissue repair.** Around 2008 or 2009 Professor Ming-Hao Zheng, experimenting with the collagen-based scaffold that he had earlier developed for Ortho-ACI\(^®\), came up with one that he argued had the ideal properties of a scaffold\(^6\). CelGro\(^®\) is simply a bio-derived collagen membrane comprised predominantly of type I collagen. Type I collagen is the type most commonly used in medicine, being the most abundant collagen type in higher-order organisms. It is a fibrillar collagen with high tensile strength and is a key component of tendons, skin, ligaments, fascia, bones and cornea\(^6\). Zheng and his collaborators were able to harness type I to a membrane manufacturing process he developed, and that was later trademarked, called SMRT\(^™\). As a result of this proprietary process, which Orthocell performs at its quality-controlled GMP facility in Perth, CelGro\(^®\) scaffolds retain the natural collagen structure from the source

---

\(^{61}\) See Orthocell’s 15 October 2015 market release headlined ‘Orthocell technologies and data to be presented at key orthopaedic conferences’.

\(^{62}\) See Orthocell’s 24 November 2014 Annual General Meeting presentation.


\(^{64}\) See the Vericel August 2017 corporate presentation, slide 16.


material. The scaffold has one rough and one smooth surface. The rough surface enhances cell attachment and infiltration, while the smooth side repels fibrous adhesions that would form damaging scar tissue. CelGro® is arguably one of the best tissue repair scaffolds yet invented. The structure of the scaffold gives it mechanical strength and pliability as well as the right porosity so that cells infiltrating the scaffold can feel at home. The high purity of the collagen, the fact that collagen is a biocompatible (and bioresorbable) natural product, and the fact that CelGro® comes without cross-linking or chemical additives, all help avoid the problems that can come with synthetic scaffolds such as toxicity and cell incompatibility. Orthocell was able to make CelGro® under GMP by about 201267.

The clinical evidence so far for CelGro® has been encouraging. As with Ortho-ATI®, Orthocell has tested CelGro® clinically in multiple indications over the last three years. The evidence suggests that CelGro® can work in both soft tissue repair as well as bone regeneration:

- In November 2015, Orthocell reported favourable results for the first two patients in a study evaluating the use of CelGro® as a barrier membrane in dental implant procedure called ‘guided bone regeneration’68.
- In June 2016, the company announced that CelGro®, was safe and tolerable68, as a tool for the surgical repair of rotator cuff tears in three study patients.
- In February 2017 Orthocell reported similar safety and tolerability from three patients in a study of CelGro® to promote regeneration in severed peripheral nerves69 while in January 2018 Orthocell reported that the positive safety and tolerability profile had extended to ten patients70.

There is plenty of data to come. There are currently four clinical studies of CelGro® ongoing which are expected to read out data over the next couple of years:

- **Guided dental bone regeneration.** The study designed to show that CelGro® is a good barrier membrane will recruit 30 patients in all. It gained ethics approval in March 201571.
- **Rotator cuff surgery.** Another 30-patient study is designed to show that CelGro® can speed the rate of surgical rotator cuff repair, thereby lowering the re-tear rate. The study was unveiled in December 201572.
- **Osteochondral defects in the hip.** ‘Microfracture’ is a common treatment for chondral defects in various joints including the hip. It involves making holes in the underlying bone, which brings a new blood supply to the surface, carrying with it marrow progenitor or stem cells that can repair the chondral defect. A 25-patient study, announced in May 2016, will see CelGro® used as the scaffold for the microfractures73. This approach has proven safe and tolerable for the first three patients74.

68 See Orthocell’s market release dated 10 November 2015 and headlined ‘Orthocell reports initial clinical results using CelGro® in dental study’.
69 See Orthocell’s market release dated 22 February 2017 and headlined ‘Initial results positive for CelGro® in human nerve regeneration’.
70 See Orthocell’s market release dated 2 January 2018 and headlined ‘Orthocell achieves 50% patient treatment milestone in human nerve regeneration trial’.
71 The ANZCTR trial ID for this study is ACTRN12615000275216 – see www.anzctr.org.au.
72 See Orthocell’s market release dated 16 December 2015 and headlined ‘Orthocell receives approval for human tendon study using CelGro’. The ANZCTR trial ID for this study is ACTRN12615000655283 – see www.anzctr.org.au. One paper has estimated that massive tears of the rotator cuff, after surgical repair, will re-tear in 57% of cases over ten years - see J Bone Joint Surg Am. 2008 Nov;90(11):2423-31.
73 See Orthocell’s market release dated 4 May 2016 and headlined ‘Orthocell receives approval for human hip study using CelGro’. The ANZCTR trial ID for this study is ACTRN12615000454460 – see www.anzctr.org.au.
74 See the Orthocell market release dated 6 September 2017 and headlined ‘CelGro® positive safety and performance in human hip study’.
Nerve regeneration. The 20-patient study evaluating CelGro® in the repair of severed peripheral nerves of the hand and upper limb was announced in October 2016.Orthocell has achieved its first approval for CelGro®. On 9 November 2017 the company announced regulatory approval (CE Mark) for the marketing and distribution of CelGro® in various dental bone and soft tissue regeneration procedures in the EU. This is the first product of a diverse suite of collagen medical devices to be commercialised from Orthocell’s CelGro® platform.

The CE Mark also validates the potential of the entire technology platform by endorsing CelGro®’s clinical performance and quality manufacturing, which will ultimately enable new applications, including:

- neurological: peripheral nerve repair;
- orthopaedic: tendon, ligaments, cartilage and bone; and
- other: general surgery (including hernia repair) and urogynecology.

For the 510(k) filing, Orthocell is using data from its guided bone regeneration and tendon repair studies and will use various existing scaffolds for its predicate device.

Why Orthocell believes CelGro® can be better than the alternatives. CelGro® will not be the only scaffold on the market when it gains approval. Indeed, there are multiple scaffolds already on the market:

- Bio-Gide, from a Swiss company called Geistlich Pharma, and BioMend Extend, from the US medical devices company Zimmer Biomet, are dental barrier membranes;
- TissueMend, from Stryker, and GraftJacket from Wright Medical are routinely used in tendon repair;
- AxoGuard, from a US biotech company called Axogen, and Neuroflex from Stryker are nerve repair scaffolds.

Orthocell believes that CelGro® is superior to these products. As we noted above, it can retain the natural collagen structure from the source material but doesn’t have the associated baggage of lipids, DNA and other non-collagen components. Moreover, it has mechanical strength without the need for cross-linking that can reduce pore size and thereby impede cell infiltration into the scaffold. Given that many large and emerging orthopaedic device companies have approved scaffolds, we see potential for CelGro® to gain licensing interest from other major medical device companies looking to enter this space.

The early indications – multiple opportunities for this versatile platform. Obviously, there are multiple indications that Orthocell can pursue with CelGro® once it gains approval. We see five in particular:

- Dental implants. A big problem in dental implants is that once a tooth disappears from gums, the bone that formerly anchored that tooth in place disappears over the next few months. When the dentist then puts an implant in place, he needs to place a bone graft substitute at the site of the implant to regenerate that bone. Trouble is, non-bone tissue will invade the area as well, hence the need for a barrier

---

75 See Orthocell’s market release dated 18 October 2016 and headlined ‘Orthocell receives approval for human nerve regeneration study using CelGro®’.
76 The ANZCTR trial ID for this study is ACTRN12616001157460 – see www.anzctr.org.au.
membrane. If Orthocell can show that CelGro® is a superior barrier membrane, the commercial upside is significant – more than 500,000 dental implant procedures are carried out every year in the US.81.

- **Rotator cuff repair.** We noted above the massive market opportunity for this indication.
- **Pelvic organ prolapse.** In this female health condition, the organs inside the pelvis protrude into the vaginal wall. Prolapse is treated via a pelvic floor reconstruction where scaffolds would be ideal to speed up healing. Possibly 6% of women over the age of 40 have experienced prolapse.82.
- **Bone regeneration.** In America, there are estimated to be >500,000 fractures p.a. where union of the bone is delayed or where there is no union.83.
- **Nerve regeneration.** Annual US incidence of nerve injury is around 1.4 million, of which 0.9 million will require surgical intervention.84.
- **ACL replacement.** Anterior Cruciate Ligament injury is a common orthopaedic problem with annual US incidence of >20,000 cases.85.

**Six trends that can make CelGro® a significant commercial success.** We believe that six factors that are becoming significant in modern medicine can help to grow the market for CelGro®:

1) **The rise of stem cells.** Since the first embryonic stem cells were isolated in 1998 there has been a significant amount of academic and applied clinical research devoted to identifying stem cells of all kinds, including autologous and allogeneic adult stem cells and, more recently, induced pluripotent stem cells, that are capable of either differentiating into specific tissue types or producing growth factors that could facilitate tissue regeneration. As this work translates into approved therapies – and companies like Mesoblast86 and TiGenix87 are now close to the market with their leading products – interest will grow in scaffolds that can place those stem cells at the required regeneration sites for optimal treatment outcomes.88.

2) **The rise of growth factors.** While more and more stem cells are being identified and characterised, the individual growth factors many of these cells produce are being isolated and harnessed for clinical use. An early example was bone morphogenic protein, a product commonly used for the last 15 years in an orthopaedic procedure called spinal fusion.89 As with stem cells, growth factor products are likely to be employed alongside scaffolds.90

3) **The push towards allogeneic therapies.** We noted previously that, as a general rule, autologous therapy means ‘higher cost’ and allogeneic therapy ‘lower cost’. Given the cost pressures in First World healthcare...
systems we think the economics of regenerative medicine will converge on scaffold-type therapies that can be delivered ‘off-the-shelf’ and draw the endogenous stem cells and growth factors to the site of tissue repair\(^91\).

4) **The interest of orthopaedic device companies at moving into biologicals.** The orthopaedic devices sector is dominated by around a dozen large, mostly US companies, including Medtronic, Stryker and Zimmer Biomet\(^92\). In recent years the orthopaedic majors have become very interested in developing or acquiring ‘orthobiologic’ products that would improve patient outcomes, as well as help them grow faster in an environment where there is less emphasis, and therefore less growth, in new ‘hardware’. Platelet-Rich Plasma is an example of this trend, as is hyaluronic acid.

5) **Greater understanding of what works in bioscaffolds.** It’s fair to say that understanding of the *in vivo* microenvironment that would allow optimal tissue regeneration is still sketchy\(^93\). As the science builds up around issues such as biomaterial-host interaction, the role of the immune system in tissue repair, and the mechanisms of stem cell recruitment, growth, and differentiation, we expect that better kinds of scaffolds with, say, a tunable pore size will be developed.

6) **Greater interest in natural product implants.** For a long time, the orthopaedics companies used synthetic materials in various implantable devices. There is now greater interest in natural products, where the material is biodegradable, in the expectation that these materials would better promote natural healing as against man-made polymers\(^94\). Collagen is a natural beneficiary of this trend given its important role in tissue structure throughout the body\(^95\), and the ease with which medical-grade collagen can be sought.

**Nerve repair is a >US$500m market for Orthocell.** A HCUP search\(^96\) suggested that in the US around 200,000 peripheral nerve repairs are performed annually\(^97\). Assume a similar rate of nerve procedures per head of

---

\(^{91}\) *Tissue Eng Part A*. 2017 May 12. (Epub ahead of print)

\(^{92}\) Other companies in this space include the privately held Arthrex, Conmed and DJO Global.


\(^{94}\) Natural scaffolds have been made out of collagen, alginate, agarose, hyaluronic acid derivatives, chitosan, and fibrin. Man-made polymers such as polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), poly(L-lactide-co-glycolide) (PLGA), and poly(lactide-co-glycolide) (PLGA) have also been tried as scaffolds.

\(^{95}\) *Biopolymers*. 2008 May;69(3):338-44.

\(^{96}\) HCUP is the Healthcare Cost and Utilization Project, a hospital use database maintained by the US government’s Agency for Healthcare Research & Quality. We used HCUP to search for all procedures that had the ICD-9 code starting with ‘04’, which encompasses ‘Operations on cranial and peripheral nerves’.

\(^{97}\) Axogen’s research has suggested a market of more like 900,000 procedures – see the page headed ‘About the nerve repair market’ on the Axogen web site.
population across Orthocell’s target markets, and further assume that only 50% of those procedures are successful, allowing Orthocell to address the other 50% with CelGro®. At US$1,500 per procedure for CelGro®, this suggests a market opportunity of >US$500m.

**Dental implants are a >US$600m market for Orthocell.** We noted above the estimate of 500,000 new dental implants in the US every year. The American Academy of Implant Dentistry doesn’t release annual figures but assume that 500,000 is a reasonable estimate. Assume a similar rate of implants per head of population across Orthocell’s target markets. At US$400 per procedure for CelGro®, this suggests a market opportunity of >US$600m.

**Orthocell is growing its pipeline of regenerative medicine opportunities**

In addition to developing Ortho-ATI® and CelGro®, Orthocell has also seeded two other intriguing early-stage opportunities:

- ‘**Lab-Grown Tendons**’. In November 2014, Orthocell announced that it had been part of a collaboration in which human tendons had been grown in a bioreactor without the need for scaffolds. Orthocell has filed for patent protection over this work. This opens up the potential for a future allogeneic tendon repair product. A grant worth A$430,000 was received in July 2015. Lab-Grown Tendons could potentially be a new treatment solution for many tendinopathies.

- ‘**Cell Factories**’ - Orthocell’s move into the allogeneic space. Led by Orthocell director Lars Lidgren, who is Professor Emeritus in the Department of Orthopaedics at Lund University in Sweden, Orthocell has built a solid body of knowledge that tissue-specific growth factors from cultured cells can work as off-the-shelf therapies for tissue repair. The company, along with a network of academic collaborators, showed *in vitro* in July 2015 that such growth factors would work in cartilage repair while in April 2016 came *in vivo* evidence that the product would also work in bone repair (although the scaffold used wasn’t CelGro® but a gelatin-based scaffold). In October 2016 the Cell Factory researchers generated further *in vitro* evidence of bone repair, this time with muscle as the scaffold.

---


98 *Partners in the collaboration alongside Orthocell were groups at the University of Western Australia, Curtin University, Griffith University and the University of Auckland.*

100 *See Orthocell’s market release dated 6 November 2014 and headlined ‘First human tendons grown in laboratory’.*


102 *From Indian Institute of Technology Kanpur, the University of Copenhagen, Oxford University, and University of Western Australia.*


Obviously both projects are early stage. However, we think that the novelty of both will find commercial appeal given the large market opportunities and, in the case of Cell Factories, the opportunity to be able to sell product ‘off the shelf’.

Valuing Orthocell

<table>
<thead>
<tr>
<th></th>
<th>Base</th>
<th>Optim.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ortho-ATI (A$m)</td>
<td>70.4</td>
<td>160.8</td>
</tr>
<tr>
<td>Ortho-ACI (A$m)</td>
<td>16.9</td>
<td>51.3</td>
</tr>
<tr>
<td>CellGro (A$m)</td>
<td>63.0</td>
<td>199.0</td>
</tr>
<tr>
<td>Value of Orthocell technology</td>
<td>150.4</td>
<td>411.1</td>
</tr>
<tr>
<td>Value of tax losses</td>
<td>5.9</td>
<td>5.9</td>
</tr>
<tr>
<td>Corporate overhead</td>
<td>-46.0</td>
<td>-46.0</td>
</tr>
<tr>
<td>Cash now (A$m)</td>
<td>4.9</td>
<td>4.9</td>
</tr>
<tr>
<td>Cash to be raised (A$m)</td>
<td>10.0</td>
<td>10.0</td>
</tr>
<tr>
<td>Option exercises (A$m)</td>
<td>9.0</td>
<td>9.0</td>
</tr>
<tr>
<td>Total value (A$m)</td>
<td>134.2</td>
<td>395.0</td>
</tr>
<tr>
<td>Total diluted shares (million)</td>
<td>150.4</td>
<td>150.4</td>
</tr>
<tr>
<td>Value per share</td>
<td>$0.892</td>
<td>$2.626</td>
</tr>
<tr>
<td>Valuation midpoint</td>
<td>$1.759</td>
<td></td>
</tr>
<tr>
<td>Share price now (A$ per share)</td>
<td>$0.290</td>
<td></td>
</tr>
<tr>
<td>Upside to midpoint</td>
<td>506.6%</td>
<td></td>
</tr>
</tbody>
</table>

We valued Orthocell at **$0.89 per share base case and $2.63 per share optimistic case** using a probability-weighted DCF approach. Our A$1.75 per share price target sits at about the midpoint of our valuation range. Our valuation approach was as follows:

- We modelled payoffs for Ortho-ATI®, Ortho-ACI® and CelGro® involving upfront and milestones payments from licensing deals but allowed no value for the Cell Factories or Lab-Grown Tendon programmes given their relatively early stage of development. We believe *in vivo* and clinical data will allow us to gradually add value from these emerging technologies.
- We assumed a 96% probability of clinical success for Ortho-ATI® and Ortho-ACI®, since the history of clinical use of these products, and the data on effectiveness that have been gathered to date, suggests no great impediment to their being approved in new markets such as the US and Europe. For CelGro® we allowed a 71% probability of success, since this is, in effect, a ‘Phase 3’ opportunity.
- Our WACC was 11% (Medium risk).
- We assume another ~US$12m in expenditure for Orthocell to mature the three product lines.
- We model around 14 years of commercial exclusivity in each case.

**Why we assumed high probabilities of clinical and regulatory success.** Historically, large molecules at Phase 3 had a high probability of succeeding in the clinic and subsequently gaining regulatory approval. For our valuation
purposes we took the historical success rate for large molecule drugs as per the figure below and applied it to Ortho-ATI®, Ortho-ACI® and CelGro®.

<table>
<thead>
<tr>
<th>LARGE MOLECULES</th>
<th>Probability of Phase success</th>
<th>Probability of gaining approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I</td>
<td>84%</td>
<td>32%</td>
</tr>
<tr>
<td>Phase II</td>
<td>53%</td>
<td>38%</td>
</tr>
<tr>
<td>Phase III</td>
<td>74%</td>
<td>71%</td>
</tr>
<tr>
<td>Filing for approval</td>
<td>96%</td>
<td>96%</td>
</tr>
</tbody>
</table>

**Why we used an 11% WACC.** A key question in developing a DCF model is the cost of capital. At NDF Research we use the following approach:

- **Risk-Free Rate.** We use the Australian Ten-Year Bond Rate, which is currently 2.8%.

- **Market Risk Premia.** We use three basic MRPs for Life Science companies - 7.5% for ‘medium risk’ companies, 9.5% for ‘high risk’ companies and 11.5% for ‘speculative’ companies. We regard Life Science companies with existing businesses, or who have enough capital to reach the market with their products, as ‘Medium’ risk. Companies that have small revenue streams from marketed products but that are still potentially in need of capital are ‘High’ risk. Everything else is ‘Speculative’. We regard Orthocell as ‘Medium Risk’.

- **Ungearred beta.** We use an ungeared beta of 1.1.

This approach suggests a discount rate for Orthocell of 11% at the present time.

**Elements of the commercial payoff for the Ortho-ACI® and CelGro® programmes – pre-launch.** We estimated, for each of the three products, a base case and an optimistic case for the following elements:

- Level of expenditure required prior to a licensing deal;
- Timing of a prospective licensing deal;
- Level of upfronds in the deal (in US$);
- Level of milestones in the deal (in US$) – note, for CelGro®, we assume no milestones given that US approval is pending, however we assume large upfronds and royalties.

**Commercial life of future products.** We assume that a product enjoys 14 years of commercial exclusivity, after which sales erode due to generic competition. While patent protection for a drug is notionally 20 years, patent

---

107 We assume that ‘low risk’ in the Life Sciences industry in Australia and New Zealand does not yet exist for most companies given the formative nature of the industry today.
term extension in the US only covers that part of clinical programme after the filing of an IND. This reduces the exclusivity window by around five or six years.

**Elements of the commercial payoff for the major programmes – post-launch.** We estimated, for each product that ultimately could be launched from the programmes, a base case and an optimistic case for the following elements:

- Date of product launch in the US;
- Date of product launch for the Rest of the World (RoW);
- Level of royalties, as a percentage of net sales;
- The level of sales (in US$) to be achieved in the US at year five post launch;
- The level of sales (in US$) to be achieved in the RoW at year five post launch;
- The growth rate of sales in both the US and the RoW between years 6 and 14;
- The percentage of the US and RoW markets still held by the product when it goes generic;
- The terminal growth rate of the product franchise.

**We summarise our assumptions on commercial outcomes in the three tables below:**

### Ortho-ATI® Project

<table>
<thead>
<tr>
<th></th>
<th>Base case</th>
<th>Optimistic case</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCC investment required (AUDm)</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>License date</td>
<td>2020</td>
<td>2019</td>
</tr>
<tr>
<td>License upfront (USDm)</td>
<td>15</td>
<td>25</td>
</tr>
<tr>
<td>License milestones (USDm)</td>
<td>50</td>
<td>80</td>
</tr>
<tr>
<td>Royalty rate</td>
<td>7.0%</td>
<td>11.0%</td>
</tr>
<tr>
<td>Earliest approval</td>
<td>2021</td>
<td>2020</td>
</tr>
<tr>
<td>Peak sales (USDm)</td>
<td>200</td>
<td>300</td>
</tr>
</tbody>
</table>

### Ortho-ACI® Project

<table>
<thead>
<tr>
<th></th>
<th>Base case</th>
<th>Optimistic case</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCC investment required (AUDm)</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>License date</td>
<td>2021</td>
<td>2021</td>
</tr>
<tr>
<td>License upfront (USDm)</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>License milestones (USDm)</td>
<td>20</td>
<td>40</td>
</tr>
<tr>
<td>Royalty rate</td>
<td>4.0%</td>
<td>7.0%</td>
</tr>
<tr>
<td>Earliest approval</td>
<td>2023</td>
<td>2022</td>
</tr>
<tr>
<td>Peak sales (USDm)</td>
<td>80</td>
<td>150</td>
</tr>
</tbody>
</table>
CelGro® Project

<table>
<thead>
<tr>
<th></th>
<th>Base case</th>
<th>Optimistic case</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCC investment required (AUDm)</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>License date</td>
<td>2021</td>
<td>2020</td>
</tr>
<tr>
<td>License upfront (USDm)</td>
<td>30</td>
<td>60</td>
</tr>
<tr>
<td>License milestones (USDm)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Royalty rate</td>
<td>10.0%</td>
<td>15.0%</td>
</tr>
<tr>
<td>Earliest approval</td>
<td>2020</td>
<td>2019</td>
</tr>
<tr>
<td>Peak sales (USDm)</td>
<td>400</td>
<td>650</td>
</tr>
</tbody>
</table>

Currency: We converted the US dollar cash flow streams into Australian dollars at the forecast exchange rates listed below:

<table>
<thead>
<tr>
<th>Half</th>
<th>AUDUSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>30/06/2018</td>
<td>0.790</td>
</tr>
<tr>
<td>31/12/2018</td>
<td>0.774</td>
</tr>
<tr>
<td>30/06/2019</td>
<td>0.759</td>
</tr>
<tr>
<td>31/12/2019</td>
<td>0.743</td>
</tr>
<tr>
<td>30/06/2020</td>
<td>0.729</td>
</tr>
<tr>
<td>31/12/2020</td>
<td>0.714</td>
</tr>
<tr>
<td>Later periods</td>
<td>0.700</td>
</tr>
</tbody>
</table>

Tax: We used the Australian corporate tax rate of 30%.

Further capital. We assume, for modelling purposes, a $10m capital raising at 40 cents per share that would help seed early commercial sales of CelGro® as well as the completion of clinical work for both CelGro® and Ortho-ATI®.

Assumptions on peak sales. We argue that we have been conservative on sales assumptions given the versatility of Orthocell’s products

Ortho-ATI®:
- We assumed usage mainly in tennis elbow and rotator cuff, with lower levels of usage in the repair of patellar tendons, Achilles tendons and so on;
- We assumed sales mainly in Europe and the US;
- We assumed pricing in the order of US$4,500 - $8,500 per procedure.
- We assumed that usage is around 2-4% of the market opportunity of ~US$8bn
**Ortho-ACI®:**

- We assumed sales only in cartilage defects in the knee – there is reasonable prospects for widening indications over time;
- We assumed sales only in Europe and the US
- We assumed pricing in the order of US$10,000 per procedure.

**CelGro®:**

- We assumed sales across only three main indications – dental, rotator cuff, and nerve regeneration;
- We assumed sales mostly in the US, with lesser market presences in Europe and the key Asian and other emerging markets
- We assumed pricing in the order of US$1,000 per unit on average (ie US$1,500 for nerve, US$400 for dental membrane).

**Re-rating Orthocell**

We see a number of events helping to re-rate Orthocell to our target price over the next 12-18 months:

- FDA and CE Mark approval for CelGro® dental, nerve, tendon and cartilage applications;
- Further clinical data for Ortho-ATI® and CelGro®;
- Early sales for CelGro® in European and US markets;
- Strategic partnerships and distribution agreements for Ortho-ATI® and CelGro®;
- Publication of the Workers Compensation retrospective study data for Ortho-ATI®;
- Progress of the Cell Factories technology into clinical studies;
- Pre-clinical progress with the Lab-Grown Tendon product.

**Orthocell’s leadership**

We think Orthocell has the leadership smarts to grow into a significant company in the tissue engineering space:

Founder and CEO **Paul Anderson** has a solid background in tissue engineering, having, as we noted above, brought the first generation Autologous Chondrocyte Implantation approach to Australia in 1999 for a German company called Verigen. Anderson started Orthocell in 2006 around a year after Genzyme had acquired Verigen. His Verigen colleague and Orthocell co-founder, CSO **Professor Ming-Hao Zheng**, brings the scientific insights that have enabled Orthocell to create Ortho-ATI® and CelGro® and to deepen its pipeline with other, more allogeneic projects. The development of this pipeline has shown that Anderson and Zheng can adapt their company to the fast pace of change in the regenerative medicine field. It’s heartening to see that the two men have sizeable ‘skin in the game’, with Zheng holding 6.7% of the company and Anderson 6.3%.
The Orthocell board has the skills required to build a serious regenerative medicine company. **Dr Stewart Washer** has a track record as a bio-entrepreneur involving many companies, including the peptide drug discovery company Phylogica108. **Matt Callahan** enjoyed a successful run with the drug reformulation company iCeutica109 and now leads the dermatology drug developer Botanix Pharmaceuticals110. **Professor Lars Lidgren** of Lund University brings considerable knowledge of the orthopaedics space.

### Appendix I – An Orthocell glossary

510(k) – Regulatory approval for a medical device in the US where the device has been found to be functionally equivalent to a device (called the ‘predicate device’) that was on the market before 1976.

**Achilles tendon** – The tendon which connects the heel bone to the muscles at the back of the calf.

**ACI** – Short for Autologous Chondrocyte Implantation – see Ortho-ACI®.

**ACL** – The Anterior Cruciate Ligament, one of the four main ligaments in the knee, binding the back of the thigh bone (femur) to the front of the shinbone (tibia).

**ARTG** – The Australian Register of Therapeutic Goods, the official list of the country’s approved medical products.

**ATI** – Short for Autologous Tenocyte Implantation – see Ortho-ATI®.

**Autologous** – A type of stem cell or tissue transplant in which the recipient receives their own cells or tissue.

**Allogeneic** – A type of stem cell or tissue transplant in which the recipient receives their cells or tissue from an unrelated donor.

**Barrier membrane** – A membrane used in guided bone regeneration to prevent unwanted tissue invading the proposed site of bone regrowth.

**Betamethasone** – See corticosteroid.

**Biopsy** – Removal of a sample of tissue from the body in order to culture it for re-implantation in cellular therapy.

**Bioreactor** – A device to synthesise biological substances.

**Bioscaffold** – A structure designed to help tissue to be regrown inside a patient’s body.

**Cartilage** – The connective tissue that covers the ends of bones in a joint.

**CelGro®** – Orthocell’s tissue repair scaffold.

---

108 Perth, ASX: PYC, www.phylogica.com.au. This company was built on a suite of ‘Phylomer’ libraries that allow new, versatile therapeutic peptides to be identified.

109 iCeutica, founded in 2005 was built around drug reformulation technology called SoluMatrix. With this dry milling process, submicron particles of commercially available drugs can be engineered, enabling those drugs to be delivered at lower doses. iCeutica was acquired by the US drug developer Iroko Pharmaceuticals in April 2011, and that company has since secured multiple FDA approvals for drugs formulated using the SoluMatrix platform.

CE marking – The process of gaining European approval for a medical device. CE stands for Conformité Européenne.

cGMP – See Good Manufacturing Practice.

Chondrocyte – A cartilage cell.

Collagen – The fibrous protein that makes up connective tissue.

Corticosteroid – Steroid hormones used in the treatment of inflammatory disorders. Betamethasone is a corticosteroid that first gained FDA approval in 1961.

Cross-links – Bonds that link one polymer chain to another.

DASH – Short for Disabilities of the Arm, Shoulder and Hand, a questionnaire to measure self-rated upper-extremity disability and symptoms.

Extensor carpi radialis brevis – The short muscle on the radial bone in the forearm whose role is to straighten the wrist.

Extracellular matrix (ECM) – The proteins that surround cells and provide structural support for them.

Fibrin – A blood clot protein often used as a glue in surgical procedures.

Gluteal tendon – The tendon associated with the gluteal muscles in the buttocks. These tendons are important because the gluteus muscles are responsible for movement of the hip and thigh.

Good Manufacturing Practice (GMP) – The set of standards that have been laid down by regulators such as the FDA for the production of clinical-grade pharmaceuticals. cGMP refers to ‘current’ Good Manufacturing Practice, since GMP standards tend to change over time.

Guided bone regeneration – A procedure in which a bone graft is placed at a site where bone regeneration is needed, and the site is protected from unwanted tissue in-growth by a barrier membrane.

In vitro – Latin for ‘in glass’, referring to data obtained through testing in a test tube.

In vivo – Latin for ‘in life’, referring to data obtained through testing in live organisms including animal models and humans.

Lateral epicondyliitis – Damage to the lateral epicondyle of the humerus. The humerus is the long bone in the arm that runs from the shoulder to the elbow. The lateral epicondyle of the humerus is the collection of tendons and muscles that help connect the humerus to the bones in the lower arm. Lateral epicondyliitis is commonly known as tennis elbow.

Ligaments – Collagen-based tissues that connect bone to bone.

MRI – Short for Magnetic Resonance Imaging, a diagnostic imaging technique in which the variable resonance of hydrogen atom to magnetic fields is used to create contrast in an image.

Open label – A clinical trial in which both patients and doctors know what treatment is being administered.

Ortho-ACI® – Orthocell’s cartilage repair product.
Ortho-ATI® – Orthocell’s tendon repair product.

Oxford Hip Score – A questionnaire that is designed to assess functional ability and pain from the patient’s perspective as a result of hip problems\(^\text{111}\).

Patellar tendon – The tendon which attaches the bottom of the kneecap (the patella) to the top of the shinbone (the tibia).

Predicate device – See 510(k).

p-value – A measure of statistical significance. Generally a p-value below 0.05 is considered ‘statistically significant’.

QuickDASH – Short for Quick Disabilities of the Arm, Shoulder and Hand\(^\text{112}\), a patient-reported outcome measure used to assess disabilities and symptoms of the upper extremity.

Rotator cuff – Tendons and muscles in the shoulder which connect the upper arm to the shoulder blade. Patients with rotator cuff injury can’t properly rotate their shoulders.

SF36 – A measurement of health-related quality of life. The PCS component of SF36 are its physical components rather than its mental components.

Soft tissue – Tissues of the body that are not bone.

Statistical significance – The probability, measured by the ‘p-value’, that an observed outcome of an experiment or trial is due to chance alone. Generally, p-values below 0.05 are taken as markers of statistical significance.

Tendinopathy – Damage to a tendon.

Tendon – The collagenous tissue which attaches a muscle to a bone.

Tenocyte – A tendon cell.

UEFS – Short for Upper Extremity Functional Scale, a ratings system for rating upper limb problems.

Visual Analogue Score (VAS) – A method of evaluating self-reported pain in which patients specify their level of pain by indicating a position along a continuous line between two end-points representing extreme pain and no pain respectively.

Appendix II – Orthocell’s intellectual property

Tenocyte cell culturing method, WO/2007/106949, priority date 23 March 2006, Invented by Ming-Hao Zheng.113

- This patent application covers the ways in which Ortho-ATI® can expand the tenocytes from the patient biopsy.

A method of producing native components, such as growth factors or extracellular matrix proteins, through cell culturing of tissue samples for tissue repair, WO/2008/043909, priority date 2 October 2006, invented by Lars Lidgren.114

- This patent application covers Orthocell’s ‘cell factory’, in which growth factors and extracellular matrix proteins are produced from cultured cells and extracted for use as an allogeneic stem cell therapy.

Tenocyte-containing bioscaffolds, WO/2008/128304, priority date 24 April 2007, Invented by Ming-Hao Zheng.115

- This patent application covers the combination of Ortho-ATI® and CelGro®.


- This patent application covers Orthocell’s CelGro® product.


- This patent application covers the use of CelGro® as an implantation system rather than just a cell-culturing system.


- This patent application covers the CelGro® manufacturing process.


- This patent application covers the adaptation of CelGro® to tissue-specific implantable scaffolds.


- This patent application covers the use of CelGro® in treating soft tissue injuries such as ACL injuries.

113 This application was granted at US Patent 7,985,408 in July 2011.
114 This application was granted in Europe as EP2076589 in February 2017; and in the US as Patent 9,220,803 in December 2015 and Patent 9,889,233 in February 2018.
115 This application was granted at US Patent 9,463,263 in October 2016.
116 This application was granted at US Patent 9,096,688 in August 2015.
Appendix III – Capital structure summary

<table>
<thead>
<tr>
<th></th>
<th>% of fully diluted</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary shares, ASX Code OCC (million)</td>
<td>110.0</td>
<td>87.7%</td>
</tr>
<tr>
<td>Unlisted options (million)</td>
<td>15.5</td>
<td>12.3% Average exercise price 58 cents, average expiry date 12-Aug-2020</td>
</tr>
<tr>
<td>Fully diluted shares</td>
<td>125.4</td>
<td></td>
</tr>
</tbody>
</table>

Current market cap: A$31.9 million (US$24.7 million)

Current share price: $0.290

Twelve month range: $0.275 - $0.495

Average turnover per day (last three months): 0.1 million

Appendix IV – Orthocell’s major shareholders

Orthocell currently has four substantial shareholders:

- **Stone Ridge Ventures** (9.3%), the Perth-based venture capital firm that seeded Orthocell, represented on the board by Matt Callahan.

- **Professor Ming-Hao Zheng** (6.7%), Orthocell’s Chief Scientific Officer, who invented the ATI and CelGro® technologies.

- **Paul Anderson** (6.3%), the founder and current CEO of Orthocell.

- **Qi Xiao Zhou** (5.8%), a Chinese businessman.
Appendix V – Papers relevant to Orthocell

- This paper showed that ACI could generate tendon healing and remodelling in animal models.

- This paper sheds some insight on the ‘natural history’ of tennis elbow as involving the death of cells in an area apart from the actual lateral epicondyle.

- This paper shows the effectiveness of ATI in animal model of Achilles tendinopathy.

- This paper reports the first clinical case of Ortho-ATI® in a 20-year-old elite gymnast with a rotator cuff tendon injury.

- This paper covers the 20-patient pilot study of Ortho-ATI® in tennis elbow.

- This paper reports continued improved function for the tennis elbow pilot study out to five years for the early patients.

- This paper demonstrates that the growth factors and extracellular matrix proteins from ‘cell factories’ can be synergistic with CelGro® scaffolds in cartilage repair.

- This paper shows that growth factors from ‘cell factories’ can enhance bond regeneration with the help of a scaffold – in this case a gelatin-based scaffold.

- This paper shows, in vivo, that growth factors from ‘cell factories’ can induce new bone growth, with muscle being used as the scaffold in this case.


- This paper reports the results of Orthocell’s 12-patient study of Ortho-ATI® in gluteal tendinopathy.

Appendix VI – Companies to watch

Anika Therapeutics. This company has been built on proprietary technologies for the manufacture of medical-grade hyaluronic acid (HA), often used in the treatment of osteoarthritis. Revenue in calendar 2017 from HA and related products was US$113m.

Histogenics. This company’s platform allows for autologous rebuilding of bone and cartilage using scaffolds and tissue processing systems. The company’s first product, NeoCart, is in Phase 3 under a Special Process Assessment for articular cartilage injuries in the knee.

InVivo Therapeutics. This company is commercialising the Neuro-Spinal Scaffold, a bioresorbable polymer scaffold that is implanted into the epicentre of a spinal cord injury to support endogenous neuroregeneration. The Neuro-Spinal Scaffold is in a pivotal study in complete thoracic spinal cord injury.

Organovo. This company, based on scaffold-free ‘bioprinting’ technology originally developed at the University of Missouri–Columbia, is working on functional, three-dimensional tissues that can potentially be implanted or delivered into the human body. At present the target market is researchers needing functional human tissue to experiment with. Kidney and liver tissue have been the first Organovo products.

Osiris Therapeutics. This company, known historically for Remestemcel-L, the first cellular therapy product for the treatment of Graft-versus Host Disease, is now growing with various scaffold and tissue repair products such as Grafix, a placental derived membrane for wound healing; Cartiform, an osteochondral mesh for cartilage repair; and BIO4, a bone matrix for bone repair.

PolarityTE. This company’s platform allows for tissue to be engineered that is ‘functionally polarised’, meaning that the cells in the tissue have the asymmetric organization that the cell is meant to exhibit. The lead product is SkinTE, for skin regeneration.

117 A product now being taken to market by the world’s leading stem cell company, Mesoblast.

118 It can do this in part through the use of stromal vascular fractions – see Plast Reconstr Surg. 2016 Feb;137(2):495-507.
**RTI Surgical.** This company, which has its origins as the allograft processing operation of the University of Florida’s Tissue Bank, has grown into a leading supplier of various tissue-based implants as well as metal and synthetic medical implants.

**Tissue Regenix.** This company’s dCELL decellularisation technology allows DNA and other cellular material from tissue to be removed from scaffolding material. The company develops decellularised scaffolds for use in wound care, orthopaedics, and cardiovascular tissue repair.

**Vericel.** This company, which in 2014 acquired Sanofi’s cell therapy and regenerative medicine business, is a developer of autologous cell therapies. The company gained FDA approval in December 2016 for MACI (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularised scaffold for repairing cartilage defects in the knee. Epicel (2017 revenue US$15.5m), a cultured epidermal autograft, is a skin replacement product for burns patients while Carticel (2017 revenue US$38.9m) is a first-generation ACI product for repair of articular cartilage defects in the knee. Vericel is also continuing to develop ixmyelocel-T, an autologous multicellular therapy intended for advanced heart failure due to ischemic dilated cardiomyopathy.\(^{119}\)

### Comparable companies to Orthocell

<table>
<thead>
<tr>
<th>Company</th>
<th>Location</th>
<th>Code</th>
<th>Market cap (USDm)</th>
<th>Web</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osiris Therapeutics</td>
<td>Columbia, Md</td>
<td>Nasdaq: OSIR</td>
<td>298</td>
<td><a href="http://www.osiris.com">www.osiris.com</a></td>
</tr>
<tr>
<td>RTI Surgical</td>
<td>Alachua, Fl.</td>
<td>Nasdaq: RTIX</td>
<td>304</td>
<td><a href="http://www.rtix.com">www.rtix.com</a></td>
</tr>
<tr>
<td>Tissue Regenix</td>
<td>Leeds, UK</td>
<td>LSE: TRX</td>
<td>139</td>
<td><a href="http://www.tissueregenix.com">www.tissueregenix.com</a></td>
</tr>
<tr>
<td>PolarityTE</td>
<td>Salt Lake City, Ut.</td>
<td>Nasdaq: COOL</td>
<td>129</td>
<td><a href="http://www.polarityte.com">www.polarityte.com</a></td>
</tr>
<tr>
<td>Organovo</td>
<td>San Diego, Ca.</td>
<td>Nasdaq: ONVO</td>
<td>122</td>
<td><a href="http://www.organovo.com">www.organovo.com</a></td>
</tr>
<tr>
<td>Histogenics</td>
<td>Waltham, Ma.</td>
<td>Nasdaq: HSGX</td>
<td>72</td>
<td><a href="http://www.histogenics.com">www.histogenics.com</a></td>
</tr>
<tr>
<td>Invivo Therapeutics</td>
<td>Cambridge, Ma.</td>
<td>OTCBB: NVIV</td>
<td>22</td>
<td><a href="http://www.invivotherapeutics.com">www.invivotherapeutics.com</a></td>
</tr>
</tbody>
</table>

\(^{119}\) As we noted in a footnote above, Vericel was formerly Aastrom Biosciences of Ann Arbor, Mi. Ixmyelocel-T was Aastrom’s lead product prior to the Sanofi transaction.
Risks related to Orthocell

Risks specific to Orthocell. We see five major risks for Orthocell as a company and as a listed stock:

- **Clinical risk.** There is the risk that Orthocell’s products may fail to meet their primary or secondary endpoints in the clinical trials into which they are taken.
- **Funding risk.** More capital will likely be needed to continue clinical development of Orthocell’s.
- **Class risk.** There is the risk that the regulatory environment for regenerative medicine products may become less liberal than is currently the case.
- **Timing risk.** There is the risk that the clinical studies we discuss in this note may take longer than we expect to complete.
- **Regulatory risk.** There is the risk that regulatory decisions may slow or stop the progress of Orthocell’s various products.

Risks related to pre-revenue Life Science companies in general.

- The stocks of biotechnology and medical device companies without revenue streams from product sales or ongoing service revenue should always be regarded as speculative in character.
- Since most biotechnology and medical device companies listed on the Australian Securities Exchange fit this description, the term ‘speculative’ can reasonably be applied to the entire sector.
- The fact that the intellectual property base of most biotechnology and medical device lies in science not generally regarded as accessible to the layman adds further to the riskiness with which the sector ought to be regarded.

*Caveat emptor.* Investors are advised to be cognisant of the abovementioned specific and general risks before buying any the stock of any biotechnology and medical device stock mentioned on this report, including Orthocell.
General Advice Warning, Disclaimers & Disclosures

The information contained herein ("Content") has been prepared and issued by NDF Research the business name of Stuart Dean Roberts, ABN 11 209 563 517 ("NDF Research"), an Authorised Representative (no: 1245466) of BR Securities Australia Pty Ltd ABN 92 168 734 530 AFSL 456663. All intellectual property relating to the Content vests with NDF Research unless otherwise noted.

Disclaimer

The Content is provided on an as is basis, without warranty (express or implied). Whilst the Content has been prepared with all reasonable care from sources we believe to be reliable, no responsibility or liability shall be accepted by NDF Research for any errors or omissions or misstatements howsoever caused. Any opinions, forecasts or recommendations reflect our judgment and assumptions at the date of publication and may change without notice. NDF Research will not accept any responsibility for updating any advice, views, opinions or recommendations contained in this document.

No guarantees or warranties regarding accuracy, completeness or fitness for purpose are provided by NDF Research, and under no circumstances will any of NDF Research, its officers, representatives, associates or agents be liable for any loss or damage, whether direct, incidental or consequential, caused by reliance on or use of the Content.

General advice warning

The Content has been prepared for general information purposes only and is not (and cannot be construed or relied upon as) personal advice nor as an offer to buy/sell/subscribe to any of the financial products mentioned herein. No investment objectives, financial circumstances or needs of any individual have been taken into consideration in the preparation of the Content.

Financial products are complex, entail risk of loss, may rise and fall, and are impacted by a range of market and economic factors, and you should always obtain professional advice to ensure trading or investing in such products is suitable for your circumstances, and ensure you obtain, read and understand any applicable offer document.

Disclosures

NDF Research has been commissioned to prepare the Content. From time to time, NDF Research’s representatives or associates may hold interests, transact or hold directorships in, or perform paid services for, companies mentioned herein. NDF Research and its associates, officers, directors and employees, may, from time to time hold securities in the companies referred to herein and may trade in those securities as principal, and in a manner which may be contrary to recommendations mentioned in this document.
NDF Research will receive fees from Orthocell, for research services and other financial services or advice we may provide to that company. The analyst has received assistance from the company in preparing this document. The company has provided the analyst with communication with senior management and information on the company and industry. As part of due diligence, the analyst has independently and critically reviewed the assistance and information provided by the company to form the opinions expressed in the report. Diligent care has been taken by the analyst to maintain an honest and fair objectivity in writing this report and making the recommendation.

Where NDF Research has been commissioned to prepare this content and receives fees for its preparation, please note that NO part of the fee, compensation or employee remuneration paid will either directly or indirectly impact the Content provided.

Recommendations

NDF Research issues a BUY recommendation in case of an expected total shareholder return (TSR, share price appreciation plus dividend yield) in excess of 25% within the next twelve months, an ACCUMULATE recommendation in case of an expected TSR between 5% and 25%, a HOLD recommendation in case of an expected TSR between -5% and +5% within the next twelve months and a SELL recommendation in case of an expected total return lower than -5% within the next twelve months.